| Title |
Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
|
|---|---|
| Published in |
Clinical, Cosmetic and Investigational Dermatology, March 2013
|
| DOI | 10.2147/ccid.s42424 |
| Pubmed ID | |
| Authors |
Vicky Ren, Harry Dao |
| Abstract |
Psoriasis is a debilitating autoimmune skin disease that affects 2%-3% of the world's population. Patients with moderate-to-severe plaque psoriasis suffer from a decreased quality of life as well as comorbidities. Newer biological agents have been shown to be more effective than traditional therapies. In this article, we assess the potential role of ixekizumab, an anti-interleukin (IL)-17 antibody, in treating moderate-to-severe plaque psoriasis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 2% |
| Unknown | 51 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 21% |
| Student > Ph. D. Student | 8 | 15% |
| Student > Doctoral Student | 7 | 13% |
| Other | 6 | 12% |
| Student > Master | 6 | 12% |
| Other | 10 | 19% |
| Unknown | 4 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 44% |
| Agricultural and Biological Sciences | 5 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Immunology and Microbiology | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 10 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2013.
All research outputs
#17,534,407
of 25,707,225 outputs
Outputs from Clinical, Cosmetic and Investigational Dermatology
#569
of 916 outputs
Outputs of similar age
#133,911
of 207,023 outputs
Outputs of similar age from Clinical, Cosmetic and Investigational Dermatology
#5
of 6 outputs
Altmetric has tracked 25,707,225 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 916 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.0. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,023 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.